Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Zidek, Walter ^a   Schrader, Joachim ^b   Lüders, Stephan ^b   Matthaei, Stephan ^c   Hasslacher, Christoph ^d   Hoyer, Joachim ^e   Zemmrich, Claudia ^f   Bramlage, Peter ^f   Sturm, Claus Dieter ^g   Paar, W D ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b St Joseph Hospital   (Germany)

^c Diabetes Zentrum   (Germany)

^d Abteilung fur Innere Medizin   (Germany)

^e Universitätskilinikum Gießen and Marburg   (Germany)

^f Institut fur Pharmakologie und Praventive Medizin   (Germany)

^g Tempestas Institut für Medizinische Forschung   (Germany)

^h Medizinische Abteilung   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; RAMIPRIL; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; CLINICAL PRACTICE; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; DRUG INTOXICATION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFECTION; INFESTATION; INJURY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MICROALBUMINURIA; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; STATISTICAL SIGNIFICANCE; THORAX DISEASE; VASCULAR DISEASE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DRUG EFFECT; GERMANY; INCIDENCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DIURETICS; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; PREDIABETIC STATE; PROSPECTIVE STUDIES; RAMIPRIL; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855518506     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-1     Document Type: Article

References (50)

1. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355(15):1551-1562.
2. Moebus S, Hanisch JU, Aidelsburger P, Bramlage P, Wasem J, Jöckel K-H. Impact of four different definitions used for assessment of the prevalence of metabolic syndrome in a primary health care setting. The German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 2007, 6(1):22. 10.1186/1475-2840-6-22, 2031874, 17822558.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
4. Lipscomb ER, Finch EA, Brizendine E, Saha CK, Hays LM, Ackermann RT. Reduced 10-year risk of coronary heart disease in patients who participated in a community-based diabetes prevention program: the DEPLOY pilot study. Diabetes Care 2009, 32(3):394-396. 10.2337/dc08-1622, 2646015, 19106377.
5. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990, 39(2):167-174. 10.1016/0026-0495(90)90071-J, 2405235.
6. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008, 31(3):596-615.
7. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43(5):963-969. 10.1161/01.HYP.0000125726.92964.ab, 15037557.
8. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369(9557):201-207. 10.1016/S0140-6736(07)60108-1, 17240286.
9. Lam SK, Owen A. Incident diabetes in clinical trials of antihypertensive drugs. Lancet 2007, 369(9572):1513-1514. author reply 1514-1515.
10. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimsky J, Zanchetti A. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006, 24(7):1405-1412. 10.1097/01.hjh.0000234122.55895.5b, 16794491.
11. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B. Ramipril and the development of diabetes. JAMA 2001, 286(15):1882-1885. 10.1001/jama.286.15.1882, 11597291.
12. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005, 112(1):48-53. 10.1161/CIRCULATIONAHA.104.528166, 15983242.
13. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 2008, 156(4):623-632. 10.1016/j.ahj.2008.05.017, 18946890.
14. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366(9489):895-906. 10.1016/S0140-6736(05)67185-1, 16154016.
15. Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005, 366(9489):907-913. 10.1016/S0140-6736(05)67186-3, 16154017.
16. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363(9426):2022-2031. 10.1016/S0140-6736(04)16451-9, 15207952.
17. McMurray, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362(16):1477-1490.
18. Dusing R, Lehnert H. Diabetogenic effect of antihypertensive treatment: primum nil nocere. Nephrol Dial Transplant 2004, 19(3):531-534. 10.1093/ndt/gfg543, 14767003.
19. Frohlich ED. Treating hypertension - what are we to believe?. N Engl J Med 2003, 348(7):639-641. 10.1056/NEJMe020179, 12584373.
20. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FHH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, . for the ACRG Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165(12):1401-1409. 10.1001/archinte.165.12.1401, 15983290, for the ACRG.
21. Luders S, Hammersen F, Kulschewski A, Venneklaas U, Zuchner C, Gansz A, Schnieders M, Pfarr E, Sturm CD, Paar WD, Schrader J. Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice. Int J Clin Pract 2005, 59(6):632-638. 10.1111/j.1742-1241.2005.00518.x, 15924589.
22. Zidek W, Schrader J, Luders S, Matthaei S, Hasslacher C, Hoyer J, Bramlage P, Sturm CD, Paar WD. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol 2008, 7:22. 10.1186/1475-2840-7-22, 2529270, 18652658.
23. Mancia G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension 2007, 25(6):1105-1187. 10.1097/HJH.0b013e3281fc975a, 17563527.
24. Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra AB. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiol J 2010, 17(5):448-456.
25. Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T, Mancia G, Volpe M. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials. Am J Hypertens 2011, 24(5):582-590. 10.1038/ajh.2011.8, 21331058.
26. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005, 23(3):463-473. 10.1097/01.hjh.0000160198.05416.72, 15716683.
27. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005, 46(5):821-826. 10.1016/j.jacc.2005.05.051, 16139131.
28. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007, 334(7588):299. 10.1136/bmj.39063.689375.55, 1796695, 17237299.
29. Geng DF, Jin DM, Wu W, Xu Y, Wang JF. Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: A meta-analysis of 59,862 patients. Int J Cardiol 2010,
30. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT, Wang X, Greene T, Appel LJ, Lewis J. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 2006, 48(5):739-751. 10.1053/j.ajkd.2006.08.004, 17059993.
31. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
32. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004, 47(9):1519-1527.
33. Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A, Ohsaka H, Matsumori R, Kurata T, Miyazaki T, Daida H. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on glucose tolerance and endothelial function - a crossover trial (AGENT). Cardiovasc Diabetol 2011, 10:79. 10.1186/1475-2840-10-79, 3179711, 21906391.
34. Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, Chiurchiu C, Barlovic DP, Sghirlanzoni A, Lombardi R, Penza P, Cavaletti G, Piatti ML, Frigeni B, Filipponi M, Rubis N, Noris G, Motterlini N, Ene-Iordache B, Gaspari F, Perna A, Zaletel J, Bossi A, Dodesini AR, Trevisan R, Remuzzi G. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 2011, 58(5):776-783. 10.1161/HYPERTENSIONAHA.111.174474, 21931073.
35. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998, 317(7151):119-120. 10.1136/bmj.317.7151.119, 28603, 9657787.
36. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003, 107(9):1291-1296. 10.1161/01.CIR.0000054611.89228.92, 12628950.
37. Nelson MR, Reid CM, Ryan P, Willson K, Yelland L. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006, 185(9):487-489.
38. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348(7):583-592. 10.1056/NEJMoa021716, 12584366.
39. ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288(23):2981-2997. 10.1001/jama.288.23.2981, 12479763, ALLHAT Collaborative Research Group.
40. Rouleau JL, Warnica WJ, Baillot R, Block PJ, Chocron S, Johnstone D, Myers MG, Calciu CD, Dalle-Ave S, Martineau P, Mormont C, van Gilst WH. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008, 117(1):24-31. 10.1161/CIRCULATIONAHA.106.685073, 18071079.
41. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351(20):2058-2068. 2556374, 15531767.
42. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353(9153):611-616. 10.1016/S0140-6736(98)05012-0, 10030325.
43. Hansson L. Results of the STOP-Hypertension-2 trial. Blood Press Suppl 2000, 2:17-20.
44. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003, 21(8):1563-1574. 10.1097/00004872-200308000-00022, 12872052.
45. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008, 51(2):393-398. 10.1161/HYPERTENSIONAHA.107.098475, 18172059.
46. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003. 10.1016/S0140-6736(02)08089-3, 11937178.
47. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362(9386):759-766. 10.1016/S0140-6736(03)14282-1, 13678868.
48. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21(5):875-886. 10.1097/00004872-200305000-00011, 12714861.
49. Yusuf S, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359(12):1225-1237. 10.1056/NEJMoa0804593, 2714258, 18753639.
50. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372(9644):1174-1183.